Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul-Aug;11(4):494-500.
doi: 10.1016/j.jceh.2020.10.008. Epub 2020 Oct 24.

Extrahepatic Malignancies and Liver Transplantation: Current Status

Narendra S Choudhary  1 , Sanjiv Saigal  1 , Neeraj Saraf  1 , Arvinder S Soin  1
Affiliations
Review

Extrahepatic Malignancies and Liver Transplantation: Current Status

Narendra S Choudhary et al. J Clin Exp Hepatol. 2021 Jul-Aug.

Abstract

Recipients of liver transplantation (LT) remain at higher risk (adjusted for other risk factors) of de novo malignancies (DNMs). The higher risk can be attributed to the effect of immunosuppression and patient-related risk factors (age, tobacco, alcohol, etiology of liver disease). DNMs are an important cause of late mortality in liver transplant recipients. The pattern (type) of posttransplant malignancies reflects pattern in local population. The common types include skin cancers, solid organ malignancies, and post-transplant lymphoproliferative disorders. Counseling of patients about risk factors and surveillance protocols may help in the prevention and diagnosis at early stage. We also discuss the results of LT in patients with a history of extrahepatic malignancy in the pretransplant period.

Keywords: DNM, de novo malignancy; EBV, Epstein–Barr virus; HR, hazard ratio; LT, liver transplantation; MPD, myeloproliferative disorder; PTLD, posttransplant lymphoproliferative disorder; SIR, standardized incidence ratios; de novo malignancy; recurrence; risk factors; smoking; surveillance.

PubMed Disclaimer

References

    1. Baccarani U., Piselli P., Serraino D. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis. 2010;42:55–60. - PubMed
    1. Pruthi J., Medkiff K.A., Esrason K.T. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transplant. 2001;7:811–815. - PubMed
    1. Baccarani U., Adani G.L., Serraino D. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc. 2009;41:1303–1305. - PubMed
    1. Schrem H., Kurok M., Kaltenborn A. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transplant. 2013;19:1252–1261. - PubMed
    1. Sérée O., Altieri M., Guillaume E. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11,226 patients. Liver Transplant. 2018;24:1425–1436. - PubMed